| Overview |
| bs-10376R-Cy3 |
| Orexin A Polyclonal Antibody, Cy3 Conjugated |
| WB, IF(IHC-P) |
| Human |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Orexin A |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 3060 |
| HCRT 1; HCRT; HCRT1; HCRT2; Hypocretin orexin neuropeptide precursor; Hypocretin 1; Hypocretin 2; Hypocretin A; Hypocretin; Hypocretin neuropeptide precursor; Hypocretin1; NRCLP1; Orexin A; Orexin; Orexin B; Orexin precursor; OrexinA; OX; PPORX; PPOX; PREPROOREXIN; OREX_HUMAN. |
| Orexin A (hypocretin 1) a 33 amino acid peptide and orexin B (hypocretin 2), a 28 amino acid peptide, are both derived from a common 130 amino acid precursor, prepro orexin. Orexin A and Orexin B stimulate food consumption when administered intracerebroventricularly to rats. Orexin gene expression in the brain is highly restricted to distinct populations of neurons located in specific hypothalamic regions, including the lateral hypothalamic area (LHA), a region implicated in feeding behaviour. Orexin A and orexin B bind to and activate two closely related G protein coupled receptors (GPCRs), termed Orexin 1 (OX1) and Orexin 2 (OX2) receptors. Dysfunction of the orexin peptide system has been linked to narcolepsy. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz